Ahmedabad, Gujarat Apr 22, 2020 (Issuewire.com) - Global FranTech Group and FranTech Los Angeles, proposing to License Stem Biotech through a Global Marketing Agreement which grants FranTech Los Angeles the right to market Stem Biotech leading-edge research and innovation with respect to relentless Innovation in Stem Cell Therapy, bringing forward scientific and clinical advancements that prevent, treat or cure life-threatening diseases through FranTech's network of 600 partners with licensing agents in 220 countries. FranTech Los Angeles will present Stem Biotech to enterprises around the world.
"In order to see the future, we must create it," says Co-Founder Dr, Nayan Shah
Through their own research, as well as partnerships with universities, medical research institutions and other global pharmaceutical leaders, Stem Biotech is bringing forward scientific and clinical advancements that prevent, treat or cure life-threatening diseases.
Dr. Dongcheng Wu, who runs a stem cell lab in Wuhan, China - the epicenter of the COVID-19 outbreak – says he has successfully treated nine critically ill patients hospitalized with coronavirus pneumonia. Stem BioTech engineers these types of unique research partnerships to provide commercial-scale helping to address the COVID-19 global pandemic.
Their research program has achieved advancements that were once thought impossible. As they bring new products into clinical development, their goal remains the same – to discover, develop and commercialize therapeutics that transform care for people around the world.
“We believe in our approach to innovation by relentlessly pursuing the best breakthroughs in science - whether they come from within our own labs or from our partnerships with other industry leaders. With new challenges and greater potential for progress than ever before, Stem Biotech is well-positioned to build on our legacy of delivering transformational treatments for patients. We are dedicated to discovering and developing lifesaving medicines, but we also recognize that science alone can’t solve the world’s toughest healthcare challenges. We believe in putting patients first and we do this in numerous ways by supporting access to healthcare services around the world and by forging partnerships with patient advocacy groups and healthcare professionals”-Says the official at Stem Biotech.
The Stem Biotech Research Spans, Chemical and Biomolecule Areas with Discovery Research, Preclinical Development and Bioanalytics.
"The Stem Biotech GMA with FranTech, because of their broad expertise, tremendous geographical reach and proven track record with more than 35 years of experience will help promote the Stem Biotech Research and innovation to new geographies where they are truly needed as FranTech knows international trade policy, law, marketing, investment banking, and technology research".
Philip Nadeau, CEO of Global FranTech Group, said: “Stem Biotech with their commitment to research and innovation in the field of Stem Cell as regenerative medicine for the treatment of chronic and life-threatening diseases coupled with their value of working with many intelligent passionate people in an inclusive work environment with every person given opportunities to learn, grow and achieve their greatest potential, having an emphasis on diversity and inclusion — is a key component to Stem Biotech's long-term and global success”.
About Stem Biotech
Relentless Innovation in Stem Cell Therapy
Through their own research, as well as partnerships with universities, medical research institutions and other global pharmaceutical leaders, Stem Biotech is bringing forward scientific and clinical advancements that prevent, treat or cure life-threatening diseases.
Dr. Dongcheng Wu, who runs a stem cell lab in Wuhan, China - the epicenter of the COVID-19 outbreak – says he has successfully treated nine critically ill patients hospitalized with coronavirus pneumonia. Stem BioTech engineers these types of unique research partnerships to provide commercial-scale helping to address the COVID-19 global pandemic.
Their research program has achieved advancements that were once thought impossible. As we bring new products into clinical development, our goal remains the same – to discover, develop and commercialize therapeutics that transform care for people around the world.
About FranTech International Licensing, Inc.
FranTech consists of core partners surrounded by interlocking networks of consultants and affiliates in key trading countries and disciplines. They have over thirty-five years of experience with their proven partners. In addition, FranTech has proven track records in assembling, negotiating and consummating trade, licensing, technological and financial agreements. They pool strengths drawn from experience in international trade policy, law, marketing, investment banking and technology research. This broad expertise, coupled with access to key government and business decision-makers, provides services uniquely valuable in the development of global enterprise. FranTech's mission is to foster the development of the world economy by providing a global perspective to developers, marketers, manufactures, and innovators of newly emerging and preemptive technologies. They offer world-class solutions for the licensing and transfer of USA innovations to emerging economies in 220 countries worldwide for over thirty-five years.
Details and a comprehensive list of business sectors can be found at http://www.FranTechWTC-3G.com
Contact Information and Submitted By:
Andrew Williams JR, President
FranTech Los Angeles
(424) 243-6580
Mobile : (213) 274-3675
Fax : (323)752-1180
AndrewWilliamsJr777@gmail.com
FranTech Neutral Zone Pvt.Ltd.
4th Floor, GIFT ONE Tower Building,56
A, Block Number: 56, Road 5 C, Zone 5, GIFT CITY
Gandhinagar, Gujarat INDIA
Media Contact
FranTech Neutral Zone frantechofficeindia@gmail.com 9265073633 56 BMM Society, http://www.frantechneutralzoneorg
